Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: Results of a randomized, double-blind, placebo-controlled trial*

This publication has 17 references indexed in Scilit:

• The CRIT Study: Anemia and blood transfusion in the critically ill—Current clinical practice in the United States*
  Critical Care Medicine, 2004
• Efficacy of Recombinant Human Erythropoietin in Critically Ill Patients
  JAMA, 2002
• Anemia and Blood Transfusion in Critically Ill Patients
  JAMA, 2002
• Nutritional deficiencies and blunted erythropoietin response as causes of the Amemia of critical illness
  Journal of Critical Care, 2001
• Response of erythropoiesis and iron metabolism to recombinant human erythropoietin in intensive care unit patients
  Critical Care Medicine, 2000
• Anemia of the critically ill: “Acute” anemia of chronic disease
  Critical Care Medicine, 2000
• Important role of nondiagnostic blood loss and blunted erythropoietic response in the anemia of medical intensive care patients
  Critical Care Medicine, 1999
• Efficacy of recombinant human erythropoietin in the critically ill patient: A randomized, double-blind, placebo-controlled trial
  Critical Care Medicine, 1999
• Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group.
  Journal of Clinical Oncology, 1997
• Erythropoietin response is blunted in critically ill patients
  Intensive Care Medicine, 1997